← Browse by Condition
Medical Condition
relapsed non hodgkin lymphoma
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 2
NCT06839456 Phase 1, Phase 2
Recruiting
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Enrollment
100 pts
Location
United States
Sponsor
Children's Hospital of Philade...
NCT05260957 Phase 2
Recruiting
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Enrollment
22 pts
Location
United States
Sponsor
Lazaros Lekakis
NCT03938987 Phase 1, Phase 2
Recruiting
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Enrollment
63 pts
Location
Canada
Sponsor
University of Alberta
NCT06484920 Phase 2
Recruiting
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Enrollment
24 pts
Location
United States
Sponsor
Rita Assi